Medicines Patent Pool mobilises leading generic drug makers to pledge for collective action against COVID-19
17 November 2020
As the COVID-19 pandemic intensifies, IDF partner Medicines Patent Pool (MPP) is mobilizing its network to encourage innovators developing new or re-purposed therapies to negotiate public health licensing agreements with MPP to allow for broader access to their know-how and intellectual property.
IDF supports this pledge as it aligns with our ongoing efforts to push for equitable access to COVID-19 diagnosis, vaccines and treatments. These are particularly important for people living with diabetes and other NCDs.